These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18221203)

  • 1. Development of new drugs that act through membrane receptors and involve an action of inverse agonism.
    Rodríguez-Puertas R; Barreda-Gómez G
    Recent Pat CNS Drug Discov; 2006 Jun; 1(2):207-17. PubMed ID: 18221203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methods to measure g-protein-coupled receptor activity for the identification of inverse agonists.
    Barreda-Gómez G; Teresa Giralt M; Rodríguez-Puertas R
    Methods Enzymol; 2010; 485():261-73. PubMed ID: 21050922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPCR drug discovery: novel ligands for CNS receptors.
    Lim WK
    Recent Pat CNS Drug Discov; 2007 Jun; 2(2):107-12. PubMed ID: 18221221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in the development of histamine H
    Łażewska D; Kieć-Kononowicz K
    Expert Opin Ther Pat; 2018 Mar; 28(3):175-196. PubMed ID: 29334795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
    Aloyo VJ; Berg KA; Spampinato U; Clarke WP; Harvey JA
    Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug targets for cognitive enhancement in neuropsychiatric disorders.
    Wallace TL; Ballard TM; Pouzet B; Riedel WJ; Wettstein JG
    Pharmacol Biochem Behav; 2011 Aug; 99(2):130-45. PubMed ID: 21463652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in histamine H3 receptor antagonists/inverse agonists.
    Łazewska D; Kieć-Kononowicz K
    Expert Opin Ther Pat; 2010 Sep; 20(9):1147-69. PubMed ID: 20716022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihistaminergics and inverse agonism: potential therapeutic applications.
    Monczor F; Fernandez N; Fitzsimons CP; Shayo C; Davio C
    Eur J Pharmacol; 2013 Sep; 715(1-3):26-32. PubMed ID: 23831018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ghrelin receptor modulators: a patent review (2011 - 2014).
    Costantino L; Barlocco D
    Expert Opin Ther Pat; 2014 Sep; 24(9):1007-19. PubMed ID: 25047815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments around histamine H(3) receptor antagonists/inverse agonists: a patent review (2010 - present).
    Łażewska D; Kieć-Kononowicz K
    Expert Opin Ther Pat; 2014 Jan; 24(1):89-111. PubMed ID: 24131059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.
    Schneider EH; Strasser A; Thurmond RL; Seifert R
    J Pharmacol Exp Ther; 2010 Aug; 334(2):513-21. PubMed ID: 20484153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverse agonism and its therapeutic significance.
    Khilnani G; Khilnani AK
    Indian J Pharmacol; 2011 Sep; 43(5):492-501. PubMed ID: 22021988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors.
    Seifert R; Wenzel-Seifert K
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):381-416. PubMed ID: 12382069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling and simulation of inverse agonism dynamics.
    Bridge LJ
    Methods Enzymol; 2010; 485():559-82. PubMed ID: 21050936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity.
    Berg KA; Clarke WP
    Int J Neuropsychopharmacol; 2018 Oct; 21(10):962-977. PubMed ID: 30085126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of histamine H₃ antagonists/inverse agonists.
    Lebois EP; Jones CK; Lindsley CW
    Curr Top Med Chem; 2011; 11(6):648-60. PubMed ID: 21261594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a High-Throughput Screening-Compatible Assay for Discovery of GPR3 Inverse Agonists Using a cAMP Biosensor.
    Ayukawa K; Suzuki C; Ogasawara H; Kinoshita T; Furuno M; Suzuki G
    SLAS Discov; 2020 Mar; 25(3):287-298. PubMed ID: 31516076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse agonism at heptahelical receptors: concept, experimental approach and therapeutic potential.
    Daeffler L; Landry Y
    Fundam Clin Pharmacol; 2000; 14(2):73-87. PubMed ID: 10796054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo.
    Millan MJ; Gobert A; Audinot V; Dekeyne A; Newman-Tancredi A
    Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):61S-67S. PubMed ID: 10432490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Techniques for studying inverse agonist activity of antidepressants at recombinant nonedited 5-HT(₂C-INI) receptor and native neuronal 5-HT(₂C) receptors.
    Seimandi M; Bockaert J; Marin P
    Methods Enzymol; 2010; 485():61-79. PubMed ID: 21050911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.